Why Ozempic May Not Work for Everyone: SDRC Investigator Anna Gloyn and Colleagues Uncover a Genetic Resistance to GLP-1 Drugs

A decade-long study finds that roughly 1 in 10 people carry genetic variants that may blunt the blood sugar-lowering effects of widely used diabetes medications — raising new questions about precision medicine in diabetes care. Read more...

Previous
Previous

New Study from the NIH Integrated Islet Distribution Program and DRCs Reveals How Human Pancreatic Islet Cell Composition Shapes Diabetes Risk

Next
Next

A Python-Derived Molecule Called pTOS Could Point to New Weight-Loss Pathways